Human therapeutic company Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) on Thursday jointly announced the receipt of approval from the US Food and Drug Administration (FDA) for KANJINTI (trastuzumab-anns) for all approved indications of the reference product, Herceptin (trastuzumab).
This includes HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
According to the partners, KANJINTI is a biosimilar to trastuzumab, a recombinant DNA-derived humanized monoclonal immunoglobulin G1 kappa antibody. The active ingredient of KANJINTI is a humanized monoclonal antibody that has the same amino acid sequence, structure and function as trastuzumab.
The drug, which has the same pharmaceutical dosage form and same strength after reconstitution as trastuzumab, was proven to be highly similar to, and to have no clinically meaningful differences from, Herceptin based on a comprehensive, extensive, comparative analytical, pharmacokinetic and clinical data.
At the time of approval, KANJINTI is the only trastuzumab biosimilar to incorporate the evaluation of a single transition in the clinical study, demonstrating similar safety and immunogenicity in patients who were previously on Herceptin. This is the third FDA approval from Amgen's biosimilars portfolio.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886